Cardiac safety is an issue causing early terminations at various stages of drug development.
Efforts are put into the elimination of false negatives as well as false positives resulting from …

Background Moxifloxacin is a recommended drug for rifampin-resistant tuberculosis (RR-TB)
treatment, but there is limited pediatric pharmacokinetic and safety data, especially in young …

Prolongation of the QT interval on an ECG is a surrogate marker for predicting the
proarrhythmic potential of a drug under development. The aim of this study was to evaluate …

Therapeutic drug monitoring (TDM) of moxifloxacin is recommended to improve the
response to tuberculosis treatment and reduce acquired drug resistance. Limited sampling …

The assessment of a drug's cardiac liability has undergone considerable metamorphosis by
regulators since International Council for Harmonization of Technical Requirement for …

Background Drug-resistant tuberculosis (DR-TB) continues to be a global threat.
Moxifloxacin is one of the components of the shorter treatment regimen which is suspected …

Understanding the physiological fluctuations in the corrected QT (QTc) interval is important
to accurately interpret the variations in drug‐induced prolongation. The present study aimed …

Background long-term use of anti-tuberculosis drugs (ATD) increases the risk of QTc
prolongation, while C-reactive protein (CRP) can be used as an inflammatory marker of …

Abstract Background: Shorter Treatment Regimen (STR) is a combination of treatments with
a shortened period from 20-24 months to 9-11 months. Shortened treatment requires a …

This study was designed to investigate ethnic differences in the pharmacokinetics (PKs) of
moxifloxacin and its metabolites, M1 (sulfo conjugate) and M2 (acyl-glucuronate), among …